Company Data

Synthorx Inc.

Current Price
Market Cap
Price Target
Refer to Report
52wk Range
$11.05 - $71.9
Advanced Market Data


Synthorx Inc is a biopharmaceutical company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. The company through its platform technology expands the genetic code by adding a new DNA base pair. Its lead product candidate includes THOR-707 a variant of IL-2 designed to kill tumor cells. It uses the Expanded Genetic Alphabet platform technology to develop cytokine Synthorins. It has designed cytokine Synthorin programs, including IL-2, IL-10 and IL-15, for the treatment of cancer, and another IL-2 Synthorin program for the treatment of autoimmune disorders.

Research Reports

    Inbox Intel from Channelchek.

    Informed investors make more money. And it’s all about timing. Get it when it happens.

    By clicking submit you are agreeing to the Terms of Use and Privacy Policy
    © 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.